A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

NCT02742519 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment.

Conditions

Cystic Fibrosis

Interventions

DRUG: ivacaftor
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated